Literature DB >> 22581359

Osteoporosis and bone health in HIV.

William G Powderly1.   

Abstract

Patients with HIV can develop several complications that involve bone including low bone mineral density and osteoporosis, osteonecrosis, and rarely osteomalacia. Low bone mineral density leading to osteoporosis is the most common bone pathology. This may result from HIV infection (directly or indirectly), antiretroviral toxicity, or as a consequence of other co-morbidities. The clinical relevance of osteoporosis in HIV infection has been uncertain; however, fragility fractures are increasingly reported in HIV-infected patients. Further research is required to understand the pathogenesis of osteoporosis in HIV-infected patients and determine effective management; however, initiation of antiretroviral therapy seems to accelerate (in the short-term) bone demineralization. Tenofovir may be associated with a greater degree of short-term loss of bone density than other antiviral agents and the potential long-term bone dysfunction is unclear. As the HIV-infected population ages, screening for low bone mineral density will become increasingly important.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22581359     DOI: 10.1007/s11904-012-0119-7

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  48 in total

1.  Mortality after all major types of osteoporotic fracture in men and women: an observational study.

Authors:  J R Center; T V Nguyen; D Schneider; P N Sambrook; J A Eisman
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

Review 2.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

3.  Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection.

Authors:  Julia H Arnsten; Ruth Freeman; Andrea A Howard; Michelle Floris-Moore; Yungtai Lo; Robert S Klein
Journal:  AIDS       Date:  2007-03-12       Impact factor: 4.177

4.  Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study.

Authors:  Michael T Yin; Chiyuan A Zhang; Donald J McMahon; David C Ferris; Dinaz Irani; Ivelisse Colon; Serge Cremers; Elizabeth Shane
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

Review 5.  HIV and bone mineral density.

Authors:  Patrick W G Mallon
Journal:  Curr Opin Infect Dis       Date:  2010-02       Impact factor: 4.915

6.  A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.

Authors:  Jeannie Huang; Linda Meixner; Susan Fernandez; J Allen McCutchan
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

7.  Continuous antiretroviral therapy decreases bone mineral density.

Authors:  Birgit Grund; Grace Peng; Cynthia L Gibert; Jennifer F Hoy; Rachel L Isaksson; Judith C Shlay; Esteban Martinez; Peter Reiss; Fehmida Visnegarwala; Andrew D Carr
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

Review 8.  CLINICAL Review # : low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis.

Authors:  Mark J Bolland; Andrew B Grey; Greg D Gamble; Ian R Reid
Journal:  J Clin Endocrinol Metab       Date:  2007-10-09       Impact factor: 5.958

9.  Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

Authors:  Allison Martin; Mark Bloch; Janaki Amin; David Baker; David A Cooper; Sean Emery; Andrew Carr
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

10.  European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

Authors:  J D Lundgren; M Battegay; G Behrens; S De Wit; G Guaraldi; C Katlama; E Martinez; D Nair; W G Powderly; P Reiss; J Sutinen; A Vigano
Journal:  HIV Med       Date:  2008-02       Impact factor: 3.180

View more
  14 in total

1.  Low bone mineral density and associated risk factors in HIV-infected patients.

Authors:  Cristina-Emilia Chiţu-Tișu; Ecaterina-Constanţa Barbu; Mihai Lazăr; Daniela Adriana Ion; Ioana Anca Bădărău
Journal:  Germs       Date:  2016-06-01

Review 2.  Osteoporosis in Human Immunodeficiency Virus Patients - An Emerging Clinical Concern.

Authors:  Filippo Maffezzoni; Teresa Porcelli; Ioannis Karamouzis; Eugenia Quiros-Roldan; Francesco Castelli; Gherardo Mazziotti; Andrea Giustina
Journal:  Eur Endocrinol       Date:  2014-02-28

3.  The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.

Authors:  Yuki Takamatsu; Debananda Das; Satoru Kohgo; Hironori Hayashi; Nicole S Delino; Stefan G Sarafianos; Hiroaki Mitsuya; Kenji Maeda
Journal:  Cell Chem Biol       Date:  2018-08-30       Impact factor: 8.116

4.  Association of Blood Biomarkers of Bone Turnover in HIV-1 Infected Individuals Receiving Anti-Retroviral Therapy (ART).

Authors:  Najib Aziz; Anthony W Butch; Joshua J Quint; Roger Detels
Journal:  J AIDS Clin Res       Date:  2014

5.  The combined effects of age and HIV on the anatomic distribution of cortical and cancellous bone in the femoral neck among men and women.

Authors:  Alison G Abraham; Jing Sun; Anjali Sharma; Michael T Yin; J Keenan Brown; Shadpour Demehri; Joshua Garza; Jayesh G Shah; Frank J Palella; Lawrence Kingsley; Beth D Jamieson; Keri N Althoff; Todd T Brown
Journal:  AIDS       Date:  2021-12-01       Impact factor: 4.632

6.  Validation of a six-item dietary calcium screening tool among HIV patients in China.

Authors:  Leslie Yingzhijie Tseng; Wenni Xie; Wei Pan; Hui Lyu; Zhangping Yu; Wenyan Shi; Yun He; Wei Chen; Taisheng Li; Evelyn Hsieh
Journal:  Public Health Nutr       Date:  2021-04-06       Impact factor: 4.022

7.  Alveolar bone in human immunodeficiency virus infection: is it changed by long-term antiretroviral therapy?

Authors:  Wipawee Nittayananta; Aree Kanjanaprapas; Pratanporn Arirachakaran; Kanokporn Pangsomboon; Hutcha Sriplung
Journal:  Int Dent J       Date:  2016-11-18       Impact factor: 2.607

8.  Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.

Authors:  Andrew Ustianowski; Joop E Arends
Journal:  Infect Dis Ther       Date:  2015-06-02

9.  Focal bone lesions in HIV-positive patient treated with tenofovir.

Authors:  Davide Mangioni; Alessandra Bandera; Antonio Muscatello; Nicola Squillace; Cinzia Crivellaro; Luca Guerra; Cristina Messa; Andrea Gori
Journal:  BMC Infect Dis       Date:  2014-03-06       Impact factor: 3.090

10.  High prevalence of low bone mass and associated factors in Korean HIV-positive male patients undergoing antiretroviral therapy.

Authors:  Pyoeng Gyun Choe; Hyung Jin Choi; Nak-Hyun Kim; Wan Beom Park; Kyoung-Ho Song; Ji Hwan Bang; Eu Suk Kim; Sang Won Park; Hong Bin Kim; Myoung-don Oh; Nam Joong Kim
Journal:  J Int AIDS Soc       Date:  2014-01-09       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.